Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Clearmind Medicine Inc. - Common Shares (NQ:CMND)

2.300 +0.100 (+4.55%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Clearmind Medicine Inc. - Common Shares

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
News headline image
Clearmind Medicine Advances Its Innovation with Newly Granted U.S. Patent, Enhancing Global Patent Strength
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Reaches Major Milestone, Completing Part A Treatment in FDA‑Regulated Phase I/II Trial
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Granted U.S. Patent for Binge Behavior Regulators
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Completes Dosing for Part A of its of FDA-Regulated Phase I/II Clinical Trial
From Clearmind Medicine Inc.
Via GlobeNewswire
Monday's pre-market session: top gainers and losers ↗
Via Chartmill
There are notable gap-ups and gap-downs in today's session. ↗
Via Chartmill
Wondering what's happening in today's pre-market session? ↗
Via Chartmill
News headline image
Clearmind Medicine to Feature New Insights from CMND-100 Psychedelic Clinical Trial on “Inside MEAI” Webinar
Yale and Johns Hopkins Researchers to Present Early Findings on MEAI Next Week in Live Webinar 
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Stocks to Watch: ANY, CMND, PRFX, OLOX, IGC Data Centers, AI, Quantum & Healthcare
Via AB Newswire
Topics Artificial Intelligence Energy Intellectual Property
Monday's session: gap up and gap down stocks ↗
Via Chartmill
Top stock movements in today's session. ↗
Via Chartmill
Friday's session: gap up and gap down stocks ↗
Via Chartmill
News headline image
Clearmind Medicine Advances Global Intellectual Property Portfolio with Japanese Patent Filing for Innovative Psychedelic- Based Depression Treatment
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Announces Johns Hopkins IRB Approval to Advance CMND-100 Phase I/II Clinical Trial to the Next Parts
From Clearmind Medicine Inc.
Via GlobeNewswire
What's going on in today's session ↗
Via Chartmill
Let's take a look at the stocks that are in motion in today's session. ↗
Via Chartmill
There are notable gap-ups and gap-downs in today's session. ↗
Via Chartmill
Wondering what's happening in today's pre-market session? ↗
Via Chartmill
News headline image
Clearmind Medicine Announces 1-for-10 Reverse Share Split
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Signs Agreement to Examine MEAI in Combination and Sequencing with Tirzepatide Against Blockbuster GLP-1 Medications
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine CEO Dr. Adi Zuloff-Shani named Delegate to Federal Policy Summit on Psychedelic Medicine in Washington, D.C.
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Reaches Important Clinical Milestone: 20 Participants Now Treated in Ongoing Phase I/IIa Trial of CMND-100 for Alcohol Use Disorder
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Announces “Inside MEAI” Webinar Featuring New Insights from CMND-100 Psychedelic Clinical Trial
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Announces Filing of European Patent Application for Novel Psychedelic Compounds for the Treatment of PTSD
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Announces Evaluation of its Psychedelic-Based Treatment (MEAI) for Potential FDA Breakthrough Therapy Designation
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Why Is Clearmind Medicine Stock Sliding On Wednesday? ↗
Clearmind Medicine Inc. (NYSE: CMND) faces a price correction Wednesday following a massive rally. Read more on the impact of CMND-100 trial results and new executive orders. 
Via Benzinga
Top movers in Tuesday's session ↗
Via Chartmill
Unusual volume stocks are being observed in Tuesday's session. ↗
Via Chartmill
These stocks are moving in today's session ↗
Via Chartmill
Traders are paying attention to the gapping stocks in Tuesday's session. ↗
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.